Document is current
Any future updates will be listed below
-
Authors
Koeglsperger, Thomas http://orcid.org/0000-0001-6101-0323
Rumpf, Svenja-Lotta
Schließer, Patricia
Struebing, Felix L.
Brendel, Matthias
Levin, Johannes
Trenkwalder, Claudia
Höglinger, Günter U.
Herms, Jochen
-
Funding
Funding for this research was provided by:
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft
- License Information
-
More Information
Article History
Received: 1 February 2023
Accepted: 21 April 2023
First Online: 12 May 2023
Declarations
:
: N.a.
: All authors consented to publish the manuscript
: We declare that we have no competing interests. J.L. reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent “Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies” (EP 23 156 122.6) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent “Pharmaceutical Composition and Methods of Use” (EP 22 159 408.8) filed by MODAG GmbH, all activities outside the submitted work.
